Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 2.720
-0.160 (-5.56%)
Aug 14, 2026, 5:29 PM CET
STO:NEWBRY Income Statement
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 35.02 | 31.57 | 36.83 | 10.27 | 5.52 | 3.09 | |
Revenue Growth | -25.14% | -14.27% | 258.75% | 86.11% | 78.73% | - |
Cost of Revenue | 25.4 | 18.74 | 20.8 | 6.32 | 3.95 | 2.58 |
Gross Profit | 9.62 | 12.83 | 16.03 | 3.95 | 1.56 | 0.5 |
Selling, General & Admin | 28.25 | 27.77 | 28.77 | 20.81 | 14.66 | 5.95 |
Other Operating Expenses | -1.97 | - | - | - | -0.12 | -0.01 |
Operating Expenses | 32.02 | 33.44 | 30.5 | 22.07 | 15.55 | 6.6 |
Operating Income | -22.4 | -20.61 | -14.47 | -18.12 | -13.99 | -6.1 |
Interest Expense | -1.86 | -1.65 | -1.53 | - | - | -0.04 |
Interest & Investment Income | 0.02 | 0.02 | 0.2 | 0.16 | - | 0.11 |
Currency Exchange Gain (Loss) | -0.81 | -0.81 | 0.39 | -1.47 | -0.68 | -0.03 |
EBT Excluding Unusual Items | -26.08 | -23.06 | -15.41 | -19.43 | -14.67 | -6.06 |
Gain (Loss) on Sale of Assets | -0.55 | -0.55 | - | - | - | - |
Pretax Income | -26.63 | -23.6 | -15.41 | -19.43 | -14.67 | -6.06 |
Income Tax Expense | 0.29 | 0.28 | -0 | - | - | - |
Net Income | -26.91 | -23.88 | -15.41 | -19.43 | -14.67 | -6.06 |
Net Income to Common | -26.91 | -23.88 | -15.41 | -19.43 | -14.67 | -6.06 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 30 | 26 | 21 | 20 | 18 | - |
Shares Outstanding (Diluted) | 30 | 26 | 21 | 20 | 18 | - |
Shares Change | 24.43% | 21.08% | 9.68% | 9.68% | - | - |
EPS (Basic) | -0.89 | -0.92 | -0.72 | -1.00 | -0.82 | - |
EPS (Diluted) | -0.89 | -0.92 | -0.72 | -1.00 | -0.82 | - |
EPS Growth | - | - | - | - | - | - |
Gross Margin | 27.47% | 40.63% | 43.53% | 38.46% | 28.35% | 16.26% |
Operating Margin | -63.96% | -65.27% | -39.29% | -176.51% | -253.57% | -197.67% |
Profit Margin | -76.85% | -75.65% | -41.83% | -189.28% | -265.90% | -196.43% |
EBITDA | -21.32 | -19.6 | -13.65 | -17.78 | -13.89 | - |
EBITDA Margin | -60.88% | -62.08% | -37.05% | -173.17% | -251.87% | - |
D&A For EBITDA | 1.08 | 1.01 | 0.82 | 0.34 | 0.09 | - |
EBIT | -22.4 | -20.61 | -14.47 | -18.12 | -13.99 | -6.1 |
EBIT Margin | -63.96% | -65.27% | -39.29% | -176.51% | -253.57% | -197.67% |
Revenue as Reported | 34.21 | 34.21 | 39.74 | 11.17 | 7.24 | 3.1 |